JP2019163319A5 - - Google Patents

Download PDF

Info

Publication number
JP2019163319A5
JP2019163319A5 JP2019104081A JP2019104081A JP2019163319A5 JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5 JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019104081 A JP2019104081 A JP 2019104081A JP 2019163319 A5 JP2019163319 A5 JP 2019163319A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
region
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019104081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019163319A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019163319A publication Critical patent/JP2019163319A/ja
Publication of JP2019163319A5 publication Critical patent/JP2019163319A5/ja
Priority to JP2021081392A priority Critical patent/JP7162695B2/ja
Pending legal-status Critical Current

Links

JP2019104081A 2013-11-21 2019-06-04 抗体−薬物コンジュゲート凍結乾燥製剤 Pending JP2019163319A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021081392A JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907001P 2013-11-21 2013-11-21
US61/907,001 2013-11-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016533019A Division JP6590803B2 (ja) 2013-11-21 2014-11-21 抗体−薬物コンジュゲート凍結乾燥製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021081392A Division JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Publications (2)

Publication Number Publication Date
JP2019163319A JP2019163319A (ja) 2019-09-26
JP2019163319A5 true JP2019163319A5 (enExample) 2020-03-19

Family

ID=51947368

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016533019A Active JP6590803B2 (ja) 2013-11-21 2014-11-21 抗体−薬物コンジュゲート凍結乾燥製剤
JP2019104081A Pending JP2019163319A (ja) 2013-11-21 2019-06-04 抗体−薬物コンジュゲート凍結乾燥製剤
JP2021081392A Active JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016533019A Active JP6590803B2 (ja) 2013-11-21 2014-11-21 抗体−薬物コンジュゲート凍結乾燥製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021081392A Active JP7162695B2 (ja) 2013-11-21 2021-05-13 抗体-薬物コンジュゲート凍結乾燥製剤

Country Status (15)

Country Link
US (3) US10617764B2 (enExample)
EP (2) EP4420729A3 (enExample)
JP (3) JP6590803B2 (enExample)
KR (1) KR102372245B1 (enExample)
CN (2) CN113521016A (enExample)
DK (1) DK3071237T3 (enExample)
ES (1) ES2983564T3 (enExample)
FI (1) FI3071237T3 (enExample)
HR (1) HRP20241036T1 (enExample)
HU (1) HUE068207T2 (enExample)
MX (1) MX377841B (enExample)
PL (1) PL3071237T3 (enExample)
PT (1) PT3071237T (enExample)
SI (1) SI3071237T1 (enExample)
WO (1) WO2015075201A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700547T1 (it) * 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
DK3071237T3 (da) * 2013-11-21 2024-09-09 Genmab As Lyofiliseret formulering af antistoflægemiddelkonjugat
WO2017009255A1 (en) * 2015-07-10 2017-01-19 Synthon Biopharmaceuticals B.V. Compositions comprising antibody-duocarmycin drug conjugates
DK3347054T3 (da) 2015-09-11 2021-07-19 Genmab As Dosisregimer til anti-TF-antistoflægemiddelkonjugater
DK3380525T3 (da) * 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
US12115227B2 (en) 2016-01-13 2024-10-15 Genmab A/S Formulation for antibody and drug conjugate thereof
SG11201810429UA (en) 2016-06-27 2018-12-28 Morphosys Ag Anti-cd19 antibody formulations
CN106938051B (zh) * 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
CR20250325A (es) * 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
UA130009C2 (uk) 2018-05-07 2025-10-15 Генмаб А/С Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
SG11202009986QA (en) 2018-05-07 2020-11-27 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
JP2021534165A (ja) * 2018-08-16 2021-12-09 ゲンマブ エー/エス 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
US20210077632A1 (en) * 2019-08-15 2021-03-18 Silverback Therapeutics, Inc. Formulations of Benzazepine Conjugates and Uses Thereof
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
AU2020380732A1 (en) 2019-11-07 2022-06-02 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
BR112022025105A2 (pt) 2020-06-29 2023-01-17 Genmab As Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco
JP2023547707A (ja) * 2020-11-10 2023-11-13 サノフイ Ceacam5抗体-薬物コンジュゲート製剤
WO2023036193A1 (zh) * 2021-09-08 2023-03-16 同宜医药(苏州)有限公司 药物制剂及其制备方法和用途
AU2022371507A1 (en) * 2021-10-19 2024-05-02 Coherent Biopharma (Suzhou) Limited Conjugate drug preparation, preparation method therefor and use thereof
CN117045634B (zh) * 2022-05-06 2025-10-10 北京康蒂尼药业股份有限公司 一种二肽衍生物组合物及其制备方法和用途
US20250302982A1 (en) 2022-05-06 2025-10-02 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
CN115656496A (zh) * 2022-10-28 2023-01-31 迪瑞医疗科技股份有限公司 一种普适型冻干保护剂及其应用
CN121039165A (zh) * 2023-04-28 2025-11-28 江苏恒瑞医药股份有限公司 抗tf抗体和抗tf抗体-药物偶联物及其医药用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
AU5093593A (en) * 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
MX9800684A (es) 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US20040038878A1 (en) 2000-08-04 2004-02-26 Masahiko Tanikawa Injectable protein formulations
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
NZ537610A (en) 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
ZA200506159B (en) 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2007034443A (ja) * 2005-07-22 2007-02-08 Konica Minolta Business Technologies Inc 画像形成システム、画像形成装置及び画像形成処理方法
ZA200800146B (en) * 2005-08-03 2009-10-28 Immunogen Inc Immunoconjugate formulations
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
KR20090001217A (ko) * 2007-06-29 2009-01-08 삼성전자주식회사 미싱 노즐 검출방법 및 이를 이용하는 잉크젯 프린트 헤드
JP4824710B2 (ja) * 2008-02-08 2011-11-30 国立清華大学 グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5005023B2 (ja) * 2009-12-25 2012-08-22 インターナショナル・ビジネス・マシーンズ・コーポレーション 読出し及び書込み命令の混在するコマンド列を受け取った場合の最適な書込みを実行するリニア記録方式の装置、その方法、及びプログラム。
RS66008B1 (sr) 2010-03-10 2024-10-31 Genmab As Monoklonska antitela protiv c-met
KR102218495B1 (ko) * 2010-03-22 2021-02-19 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
SMT201700547T1 (it) 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
DK3071237T3 (da) * 2013-11-21 2024-09-09 Genmab As Lyofiliseret formulering af antistoflægemiddelkonjugat
DK3347054T3 (da) 2015-09-11 2021-07-19 Genmab As Dosisregimer til anti-TF-antistoflægemiddelkonjugater

Similar Documents

Publication Publication Date Title
JP2019163319A5 (enExample)
US12121527B2 (en) Anthracycline-based antibody drug conjugates having high in vivo tolerability
KR100812658B1 (ko) 향상된 세포독성 및 수율의 항-이지에프알브이 3,에스씨에프브이에스, 이에 기초한 면역독소, 및 이의 이용방법
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
JP7718816B2 (ja) 抗メソセリン抗体およびその抗体薬物コンジュゲート
JP6616776B2 (ja) 抗体−薬物複合体及び免疫毒素
ES2788864T3 (es) Conjugados de anticuerpo-fármaco e inmunotoxinas
JP6585600B2 (ja) C末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法
JP2021516960A5 (enExample)
US11278628B2 (en) Pharmaceutical formulations and methods of use thereof
JP2020509031A5 (enExample)
KR20160079890A (ko) 항체-약물 접합체 동결건조 제제
CN1816356A (zh) 药物缀合物组合物
KR102399028B1 (ko) 이중-특이적 항원-결합 폴리펩티드
RU2020112280A (ru) Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение
WO2004064787A3 (en) Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
IL273384B2 (en) Methods of preventing methionine oxidation in immunoconjugates
CN119317447A (zh) 抗可变muc1*抗体及其用途
CN113795513A (zh) 抗外周淋巴结地址素抗体及其用途
US20240091372A1 (en) Anti-doppel antibody drug conjugates
US20170326252A1 (en) Nanoparticles for Delivery of Agents to Glioblastoma Tumors
HK1092730A (en) Drug conjugate composition